Clinical Trials Logo

Clinical Trial Summary

This study will develop a therapy for men who have sex with men who also have a history of childhood sexual abuse to reduce behaviors that put them at a high risk of HIV infection.


Clinical Trial Description

Men who have sex with men (MSM) represent the largest group of new HIV infections. Rates of childhood sexual abuse (CSA) in MSM have been estimated to be higher than in the rest of the population, with some researchers estimating that 37% of all MSM have experienced CSA. CSA in MSM is associated with both higher rates of HIV risk behavior and higher rates of HIV infection. Treatments for preventing HIV are also less likely to be effective in MSM with a history of CSA, and these individuals tend to have higher rates of depression, anxiety, substance abuse, and post-traumatic stress disorder (PTSD) symptoms. This study will create and then test a new HIV prevention therapy that addresses both HIV risk behaviors and the co-occurring psychological health problems in MSM with a history of CSA.

This study includes a pilot phase and an experimental phase. In the pilot phase, the therapeutic treatment will be developed based on elements of successful interventions for reducing sexual risk-taking behaviors and PTSD symptoms. Information-motivation-behavioral (IMB) skills training for sexual risk reduction will be the basis for one of two treatment components, and it is expected to last for two 50-minute sessions. This intervention will include addressing knowledge about issues surrounding sexual risk, using motivational interviewing to address goals and self-efficacy, and providing strategies for behavioral change. Cognitive processing therapy (CPT) for CSA will be the basis for the other component and is expected to last for eight 50-minute sessions. Elements of this intervention will include identifying sexual abuse events, learning how to identify cognitive distortions, and learning processes to challenge and process these distortions.

During the pilot phase, approximately 10 participants will undergo the new treatment. After completing the treatment sessions, participants will undergo exit interviews, in which researchers will solicit feedback about the strengths and weaknesses of the treatment. This feedback will be used to fine tune the treatment.

During the second phase of the study, approximately 50 individuals will be randomly assigned to receive either HIV testing with pre/post-test counseling alone or in combination with the newly developed treatment. The experimental, integrated treatment will be administered over 10 individual therapy sessions comprised of sexual risk reduction counseling and cognitive therapy.

All participants will undergo assessments at enrollment and after treatment (or approximately 3 months after enrollment in comparator group), and at follow-up visits 6 and 9 months after enrollment. These assessments will measure sexual risk behaviors, PTSD symptoms, distress, social support, and substance abuse. Brief questionnaires about sexual behavior and measures of distress will be administered during the integrated treatment sessions. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00797654
Study type Interventional
Source Fenway Community Health
Contact
Status Completed
Phase N/A
Start date August 2008
Completion date May 2011

See also
  Status Clinical Trial Phase
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT05509270 - Efficacy of Communication Modalities for Promoting Flu Shots N/A
Completed NCT05343208 - Effectiveness of Online Therapy to Prevent Burnout N/A
Completed NCT03833713 - Utilizing Text Messaging to Improve Vehicle Safety Among At-Risk Young Adults N/A
Recruiting NCT06001892 - Tennessee Youth Prepared for Success N/A
Completed NCT04323137 - Encouraging Flu Vaccination Among High-Risk Patients Identified by ML N/A
Recruiting NCT03109899 - Personalized HIV and STI Testing Tool N/A
Recruiting NCT05017948 - Alleviating Geriatric Inpatients' Medication-related Iatrogenesis N/A
Completed NCT05509283 - Nudging Flu Vaccination in Patients at Moderately High Risk for Flu and Flu-related Complications N/A
Recruiting NCT05353283 - PrEP Point-of-Care Brief-Intervention for Adherence Among Young Men Who Have Sex With Men N/A
Recruiting NCT04294381 - Achievement and Adherence to Behavioral Health Goals in the Setting of Patient-Directed Goal Choice N/A
Recruiting NCT04500977 - Training Health Promotion Women Community Leaders N/A
Recruiting NCT03319927 - Reducing Pesticide Exposures in Child Care Centers N/A
Completed NCT03981952 - Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine Phase 1
Completed NCT03177512 - LYNX: A Novel Mobile App to Support Linkage to HIV/STI Testing PrEP for Young Men Who Have Sex With Men N/A
Recruiting NCT04374747 - Fruit and Vegetable Intervention in Lactating Women to Reduce Breast Cancer Risk N/A
Recruiting NCT06020469 - Comparative Effects of Ciprofol and Propofol on Pain Intensity on the First Day After Surgery: a Retrospective, Propensity Score Matched, Cohort Study
Recruiting NCT05569460 - Construction of Perioperative Medical Data Platform and Its Typical Practice to Predict Postoperative Acute Moderate to Severe Pain With Machine Learning Models
Not yet recruiting NCT03222960 - Improving Caries Risk Using Propolis-containing Versus Fluoride-containing Toothpastes in High Caries Risk Patients N/A
Completed NCT03965221 - Comparison of Men's Prevention Apps to Research Efficacy N/A